BioSpace News Archive

Initial safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1/2 clinical trial for KB-0742 expected in fourth quarter of 2021

KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1 Interferon pathways resulting in superior antitumor activity in MYD88-mutant DLBCL models compared to IMiDs or selective IRAK4 targeting alone

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, announced preclinical data at the American Association for Cancer Research Annual Meeting that expands the utility of its TurboCAR™ technology platform to address specific biology of solid tumor oncology.

Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a cell penetrating antibody, to non-covalently bind to and systemically deliver therapeutic levels of multiple types of nucleic acid payloads to cells in vitro and tumors in vivo

Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced presentations at the American Association for Cancer Research Annual Meeting, taking place April 10-15, 2021.

Vincerx Pharma, Inc. is a biopharmaceutical company aspiring to address the unmet medical needs of cancer patients through paradigm-shifting therapeutics.

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, announced the presentation of preclinical data on BDTX-189 and BDTX-1535 at the American Association for Cancer Research Annual Meeting, taking place April 9-14, 2021.

Bolt’s first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase 1/2 first-in-human study

Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202